Key result
Combined lisinopril and moxonidine normalizes blood pressure in ~89% of patients versus either monotherapy.
Why the study?
Does combined therapy with lisinopril and moxonidine improve blood pressure normalization compared to monotherapy in patients with metabolic syndrome and moderate hypertension?
RCT (n=57)
Does combined therapy with lisinopril and moxonidine improve blood pressure normalization compared to monotherapy in patients with metabolic syndrome and moderate hypertension?
Absolute Event Rate: 89.4% vs 47.3%
p-value: p=0.002
Combined treatment with lisinopril and moxonidine significantly improves blood pressure normalization and lipid profiles compared to monotherapy in patients with metabolic syndrome.
Combination may raise BP control rates in metabolic syndrome hypertension; leaves open need for outcome trials versus monotherapy.
Objective: Hypertension is the one of the most common risk factor of coronary heart disease in patients with metabolic syndrome. Over the last few decades, a number of classes of anti-hypertensive drugs have been used to treat hypertension, with the ultimate goal of reducing the incidence of endpoints such as heart attacks and stroke. Aim of this study was to assess efficacy of monotherapy with ACE inhibitor lisinopril or I1-imidazoline receptor agonist moxonidine and their combination in patients with MS. Design and Method: The study enrolled 57 patients (31 females, 26 males; mean age 52 ± 9.6 years old) with MS. All patients were divided into 3 groups with 19 patients per group. The first group 5.0 mg lisinopril, the second group 0.2 mg moxonidine and the third group 5.0 mg lisinopril and 0.2 mg monoxidine were provided. The examination at baseline and after 4, 8 and 12 weeks of treatment included office blood pressure (BP) measurement, 24-hour BP monitoring, heart rate variability (HRV), parameters of lipid profile and fasting blood glucose estimation. Results: In moderate hypertension BP normalized in 47.3 % and 57.8 % on monotherapy with lisinopril or moxonidine, respectively (P < 0.02), and in 89.4 % patients given lisinopril + moxonidine (P = 0.002) after 12 weeks treatment. No changes of lipid profile occurred in the first group of patients while significant elevation of high density lipoprotein cholesterol and tendency to lowering of triglyceride level were observed in second and third groups. Conclusions: Combined treatment with lisinopril and moxonidine is more effective than monotherapy with each of the above drugs in patients with metabolic syndrome. Further confirmations are required.
No takes yet. Share an insight, caveat, or question.
Uzokov et al. (2016) conducted an RCT in Metabolic syndrome and moderate hypertension (n=57). Lisinopril and moxonidine combination vs. Lisinopril monotherapy or moxonidine monotherapy was evaluated on Blood pressure normalization (p=0.002). Combined treatment with lisinopril and moxonidine normalized blood pressure in 89.4% of patients, compared to 47.3% with lisinopril and 57.8% with moxonidine monotherapy (P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: